報價延遲最少15分鐘:2025/11/07 18:37 EST
盤後時段
|
||||
|
2.08 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.03
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.16/-0.05
|
|
企業價值
32.70M
|
| 資產負債 |
|
每股賬面淨值
1.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
66.38M
|
|
每股收益
10.54
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/07 18:37 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties. |
